1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
DocMorris AG

DocMorris AG

ZRSEF
DocMorris AGUS flagOther OTC
10.24
USD
- -
- -
497.86MMarket Cap
DocMorris AG
ZRSEF
(Other OTC)

Recent

price

10.24

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
FRC
- -
53.02
75.3
80.66
132.45
133.22
121.04
95.49
92.76
93.63
77.04
80.13
88.14
42.54
40.89
42.47
Revenue per Share
- -
0.43
1.34
0.95
-2.25
1.04
0.5
-1.39
-3.42
-3.02
-2.98
-7.36
-11.52
-7.82
3.47
-4.06
Basic EPS, GAAP
- -
0.95
-0.04
2.44
-1.26
-1.26
0.53
-3.66
-4.14
-5.02
-7.05
-6.91
-9.91
-6.57
-5.01
-2.31
Free Cash Flow per Basic Share
- -
0.62
0.58
0.23
0.22
- -
0.28
0.18
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
6.45
10.38
11.17
8.19
8.96
9.23
6.35
3.38
1.06
9.99
6.16
-4.1
-8.19
-3.83
-6.34
Book Value per Share
- -
5.36
8.16
5.51
3.35
3.94
2.76
4.42
13.84
13.88
-3.39
-3.95
-5.64
-10.11
-2.72
-6.45
Tangible Book Value per Share
- -
9
6
6
7
7
7
9
11
13
18
18
20
22
24
24
Basic Weighted Avg Shares
- -
488
487
523
911
916
834
880
983
1,207
1,356
1,477
1,727
931
969
1,017
Sales/Revenue/Turnover
- -
1.43
0.85
0.42
-0.68
0.85
0.96
-0.86
-3.94
-2.76
-4.76
-8
-11.33
-16.2
-8.52
-10.25
Operating Margin (%)
- -
7
5
5
8
9
7
9
17
19
32
39
51
40
43
46
Depreciation Expense
- -
4
9
6
-15
7
3
-13
-36
-39
-52
-136
-226
-171
82
-97
Net Income, GAAP
- -
22.69
- -
6.29
- -
- -
14.79
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
0.8
1.78
1.17
-1.7
0.78
0.41
-1.45
-3.69
-3.23
-3.86
-9.19
-13.07
-18.38
8.49
-9.56
Profit Margin (%)
34
31
28
91
63
61
54
21
154
298
215
383
325
155
113
97
Working Capital
8
6
- -
77
58
58
62
9
3
116
349
520
520
493
236
308
LT Debt
90
79
82
86
73
77
73
104
294
444
406
532
485
351
431
340
Total Equity
- -
4.63
- -
1.51
- -
- -
4.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
5.74
- -
5.75
- -
- -
4.5
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
6.46
13.71
8.8
-24.03
12.14
5.5
-20.91
-76.86
-157.58
-55.26
-93.81
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.88%
-0.72%
-21%
Free Cash Flow
-104.08%
-8.36%
-53.51%
Net Income, GAAP
-46.18%
-32.99%
-218.2%
Sales/Revenue/Turnover
3.22%
-2.24%
4.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
969
2024
- -
- -
- -
- -
1,017
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3.47
2024
- -
- -
- -
- -
-4.06
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
MakingORG, Inc. (CQCQ)
MEDirect Latino, Inc. (MLTO)
Galenica AG (GALNF)
Gujarat Inject (Kerala) Ltd. (GUJINJEC.BO)
ClouDr Group Limited (9955.HK)
Profarma Distribuidora de Produtos Farmacêuticos S.A. (PFRM3.SA)
Business
DocMorris AG DocMorris AG (ZRSEF) operates as a leading European online pharmacy, telemedicine provider, and digital health platform, offering e-commerce pharmacies, wholesale distribution of medical and pharmaceutical products, and professional healthcare services primarily in Germany, Switzerland, the Netherlands, Spain, France, and other European markets. Founded in 1993 and headquartered in Frauenfeld, Switzerland, the company delivers prescription (Rx) and over-the-counter (OTC) medicines, consumer health products, beauty and personal care items, nutritional supplements, painkillers, first aid products, and private-label OTC offerings through brands including DocMorris, PromoFarma by DocMorris, TeleClinic, and Zur Rose; it also provides marketplace services with over 1,500 pharmacy and seller partners for assortment expansion and same-day express delivery via DocMorris Express, alongside professional services such as telemedicine consultations with 1,500 doctors, digital health journeys for chronic conditions like diabetes and obesity, partnerships with pharmaceutical companies on platforms like DocMorris Ratgeber, and solutions for health insurers including medication management, e-prescriptions, direct billing, and pharmaceutical advice. DocMorris AG changed its name from Zur Rose Group AG in May 2023 to unify its branding under the DocMorris identity; in 2024, it achieved revenue and earnings targets with non-Rx business profitability, tripled new Rx customers due to Germany's e-prescription rollout and CardLink introduction in April, grew active customers to 10.3 million, and reduced CO2e emissions by 67%; in early 2025, it reported 52% Rx revenue growth, secured a fully underwritten CHF 200 million capital increase to fund customer acquisition and potential convertible bond refinancing, announced tender offer results for its 2026 convertible bonds, and projects over 10% external revenue growth with sequential Rx acceleration.

Company News

APIChat

  • seekingalpha.com

    DocMorris AG (ZRSEF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    DocMorris AG (ZRSEF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    DocMorris AG (ZRSEF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    DocMorris AG (ZRSEF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    DocMorris AG (ZRSEF) Q2 2024 Earnings Call Transcript

  • seekingalpha.com

    DocMorris AG (ZRSEF) Q4 2023 Earnings Call Transcript

  • reuters.com

    Online drug retailer DocMorris meets expectations as cost savings help

  • reuters.com

    Online drug retailer DocMorris trims top end of 2023 outlook